The United States has a dominant position in the global life sciences market, and expanding into the US is a strategic objective of paramount importance for many early-stage European life sciences companies. To successfully penetrate this lucrative market, startups must carefully assess their capital needs, determine the most appropriate form of funding and nature of potential investors, and establish a suitable legal framework for their expansion.
Authors:
|
|
|
|
|
|
|
|